1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Japan Pharmaceuticals and Healthcare Report Q2 2016

Japan Pharmaceuticals and Healthcare Report Q2 2016

  • February 2016
  • -
  • Business Monitor International
  • -
  • 122 pages

Includes 3 FREE quarterly updates


BMI View:
Japanese pharmaceutical firms will be forced to adapt their business model to accommodate the changing domestic medicine landscape. With the market share of generic drugs expected to grow in line with government incentives, Japan-based drugmakers will see revenues from long-listed products come under increasing pressure. For research-based firms, innovation will become the key to navigate this business environment which necessitates a focus on core competencies.


Headline Expenditure Projections
- Pharmaceuticals: JPY11.5trn (USD94.9bn) in 2015 to JPY11.7trn (USD101.6bn) by 2016 with a y-o-y growth of 2.2% in local currency terms and -7.1% in USD terms.
- Healthcare: JPY51.3trn (USD432.8bn) in 2015 to JPY52.3trn (USD439.7bn) in 2016 with a y-o-y growth of 2.0% in local currency terms and 1.6% in USD terms. Healthcare spending revised downwards
due to new data from the World Health Organization. The lower US dollar amount is driven by the weakening of the yen against the dollar.

Table Of Contents

Japan Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View ... 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Japan 2014-2020) . . 7
SWOT 9
Industry Forecast .. 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Japan 2012-2020) . . 13
Healthcare Market Forecast .. 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2012-2020) . . 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2012-2020) . 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Japan 2012-2020) . 20
Patented Drug Market Forecast . 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Japan 2012-2020) . 22
Generic Drug Market Forecast .. 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Japan 2012-2020) . . 25
OTC Medicine Market Forecast . 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Japan 2012-2020) 28
Pharmaceutical Trade Forecast . 29
Table: Pharmaceutical Trade Data And Forecasts (Japan 2014-2020) . 30
Table: Pharmaceutical Trade Data And Forecasts local currency (Japan 2014-2020) 31
Industry Risk Reward Index . 32
Asia Pacific Risk/Reward Index .. 32
Japan Risk/Reward Index .. 38
Rewards ... 38
Risks 38
Regulatory Review 40
Regulatory Development ... 40
Table: Re-examination Period . . 45
Pricing and Reimbursement 45
Market Overview ... 47
Healthcare Sector .. 47
Table: Healthcare Resources (Japan 2010-2015) 48
Table: Healthcare Personnel (Japan 2010-2015) 49
Table: Healthcare Activity (Japan 2010-2015) 49
Research and Development 49
Clinical Trials ... 50
Epidemiology 51
Table: Estimated Number Of New Cases Of Cancer In Japan . . 53
Table: Japan: Dementia Cases And Types Across Different Areas 54
Competitive Landscape 56
Research-Based Industry . 56
Table: Companies Represented By The JPMA 56
Table: Multinational Pharmaceutical Firm Activity . 57
Generic Drug Industry 59
Table: Members Of The Japan Generic Medicines Association . 60
Pharmaceutical Distribution 60
Pharmaceutical Retail Sector ... 62
Company Profile 63
Astellas .. 63
AstraZeneca ... 68
Daiichi Sankyo 71
Eisai . 75
GlaxoSmithKline . 81
Merck and Co 85
Mitsubishi Tanabe ... 88
Novartis . 91
Pfizer 96
Sanofi .. 100
Sawai Pharmaceutical 103
Takeda Pharmaceutical Company . 106
Demographic Forecast ... 111
Demographic Outlook 111
Table: Population Headline Indicators (Japan 1990-2025) . 112
Table: Key Population Ratios (Japan 1990-2025) . 112
Table: Urban/Rural Population and Life Expectancy (Japan 1990-2025) 113
Table: Population By Age Group (Japan 1990-2025) . 113
Table: Population By Age Group % (Japan 1990-2025) . 114
Glossary ... 116
Methodology 118
Pharmaceutical Expenditure Forecast Model 118
Healthcare Expenditure Forecast Model ... 118
Notes On Methodology .. 119
Risk/Reward Index Methodology . 120
Index Overview 121
Table: Pharmaceutical Risk/Reward Index Indicators 121
Indicator Weightings 122

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.